STATEMENT OF EDITORIAL PURPOSE
The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board examinations in gastroenterology. Each quarterly manual reviews a topic essential to the current practice of gastroenterology.

PUBLISHING STAFF
PRESIDENT, GROUP PUBLISHER
Bruce M. White
EDITORIAL DIRECTOR
Debra Dreger
SENIOR EDITOR
Becky Krumm
ASSISTANT EDITOR
Rita E. Gould
EXECUTIVE VICE PRESIDENT
Barbara T. White
EXECUTIVE DIRECTOR
OF OPERATIONS
Jean M. Gaul
PRODUCTION DIRECTOR
Suzanne S. Banish
PRODUCTION ASSISTANT
Kathryn K. Johnson
ADVERTISING/PROJECT MANAGER
Patricia Payne Castle
SALES & MARKETING MANAGER
Deborah D. Chavis

NOTE FROM THE PUBLISHER:
This publication has been developed without involvement of or review by the American Board of Internal Medicine.

Endorsed by the Association for Hospital Medical Education

NSAID-Induced Gastrointestinal Damage

Series Editor:
Robert M. Craig, MD
Professor of Medicine, Division of Gastroenterology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL

Contributor:
James M. Scheiman, MD
Professor of Medicine, Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, MI

Table of Contents

Introduction .............................................. 2
Assessing Risk ........................................... 2
Pathogenesis ............................................. 4
Management ............................................. 5
Preventive Strategies ................................... 6
NSAID-Induced Small Bowel and Colonic Disease ......................... 10
References ............................................... 10

Cover Illustration by Scott Holladay

Copyright 2004, Turner White Communications, Inc., 125 Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications, Inc. The editors are solely responsible for selecting content. Although the editors take great care to ensure accuracy, Turner White Communications, Inc., will not be liable for any errors of omission or inaccuracies in this publication. Opinions expressed are those of the authors and do not necessarily reflect those of Turner White Communications, Inc.
INTRODUCTION

CASE PRESENTATION

It’s 5:30 AM, and you’ve just left the intensive care unit following successful endoscopic therapy to control a bleeding gastric ulcer in a 55-year-old man. He was generally healthy, but he was taking “one of those new, safer, NSAIDs” for knee osteoarthritis. He also had been taking an enteric-coated aspirin at night, because “all his friends take one, too.” He takes no other medications. At the time of the endoscopy, biopsies were obtained for Helicobacter pylori status.

EPIDEMIOLOGY OF NSAID-INDUCED ULCERS

Each year, more than 40 billion aspirin tablets are consumed and more than 110 million prescriptions for nonsteroidal anti-inflammatory drugs (NSAIDs) are filled in the United States. At least one third of the prescriptions are for cyclooxygenase (COX)-2–specific inhibitors (coxibs) at a cost of $5 billion dollars/yearly.1 These drugs can have significant adverse gastrointestinal (GI) effects ranging from symptoms such as nausea and dyspepsia (ie, persistent pain or discomfort in the upper abdomen) to serious ulcer complications such as bleeding and perforation. Among chronic NSAID users (defined as daily use for more than 1 year), the risk of developing a symptomatic ulcer, gastrointestinal bleed, or perforation is 1% to 4%.2

Although there is a low probability that any individual NSAID user will experience a drug-related complication, the huge number of chronic users translates NSAID toxicity into a major health care problem. It is estimated that more than 100,000 hospitalizations and up to 10,000 to 20,000 deaths each year in the United States can be attributed to NSAID complications.2

There is no consensus among clinicians on how best to weigh the potential clinical benefits of various anti-inflammatory agents against the possibility of adverse events associated with their use. Choosing between a generic traditional NSAID and the safer but more costly medications in the COX-2–specific inhibitor class requires a framework for informed decision making.

Considerations include the patient’s risk for toxicity, the need for concurrent aspirin therapy, and whether the patient is already taking a gastroprotective agent such as a proton pump inhibitor (PPI). Patient risk factors should drive clinical decision making to target these medications in cost-effective manner.

ASSESSING RISK

NSAID users have an approximately 3-fold elevated risk of an ulcer complication (ie, bleeding, perforation, or a clinical event requiring hospitalization or causing death) compared to nonusers. Although 1% to 4% of chronic NSAID users develop an adverse event, individual risk varies considerably across the population. When chronic NSAID therapy is necessary, it is essential to assess a patient’s individual risk for complications. Recognized risk factors (in order of their relative importance) are listed in Table 1.

RECENT OUTCOME STUDIES

Until the recent CLASS3 and VIGOR4 outcome studies were completed evaluating the safety of coxibs (celecoxib and rofecoxib, respectively) compared to traditional NSAIDs, the only prospective data regarding the risk of serious complications due to NSAIDs was from the MUCOSA5 trial, which compared the outcome of rheumatoid arthritis (RA) patients taking non-aspirin NSAIDs plus either misoprostol or placebo. 0.95% of patients on non-aspirin NSAIDs plus placebo developed serious GI complications within 6 months as compared to 0.57% of patients on NSAIDs plus misoprostol. These findings are consistent with the frequently quoted 2% to 4% risk included in the prescribing information for prescription NSAIDs. The CLASS and VIGOR studies confirmed these rates—approximately 2% annually for complicated ulcers, and 4% annually for symptomatic ulcers.3,4

RISK FACTORS

Patients with a history of ulcer complications and those taking concomitant anticoagulant therapy have the highest risk of developing NSAID-associated serious GI complications. Moderate risk factors include advanced age,